Observers say that while capping the cost of insulin at $35 a month benefits consumers, it doesn't strengthen Lilly's legal arguments since the company and others raised list prices by 150% over five years, alleges one lawsuit.
"I wholeheartedly disagree with noncompetes at any level," said Sameer Baig, a Florida doctor who says huge health care companies use them to get the upper hand on physicians who might otherwise leave.